关键信息
-
基因名
B3GNT7
- 应用
-
别名
B3GNT7；UDP-GlcNAc:betaGal beta-1.3-N-acetylglucosaminyltransferase 7
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8NFL0
-
表达区间
27-401aa
-
氨基酸序列
RSLTPGQFLQEPPPPTLEPQKAQKPNGQLVNPNNFWKNPKDVAAPTPMASQGPQAWDVTTTNCSANINLTHQPWFQVLEPQFRQFLFYRHCRYFPMLLNHPEKCRGDVYLLVVVKSVITQHDRREAIRQTWGRERQSAGGGRGAVRTLFLLGTASKQEERTHYQQLLAYEDRLYGDILQWGFLDTFFNLTLKEIHFLKWLDIYCPHVPFIFKGDDDVFVNPTNLLEFLADRQPQENLFVGDVLQHARPIRRKDNKYYIPGALYGKASYPPYAGGGGFLMAGSLARRLHHACDTLELYPIDDVFLGMCLEVLGVQPTAHEGFKTFGISRNRNSRMNKEPCFFRAMLVVHKLLPPELLAMWGLVHSNLTCSRKLQVL
-
分子量
50.5 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
B3GNT7, or Beta-1,3-N-acetylglucosaminyltransferase 7, is a crucial enzyme involved in glycosylation processes, specifically in the synthesis of glycosaminoglycans. It plays a vital role in cell signaling, cell adhesion, and various biological processes essential for normal physiology. Dysregulation of B3GNT7 has been linked to various diseases, including cancer, where altered glycosylation patterns can influence tumor progression and metastasis. The research on B3GNT7 recombinant proteins focuses on understanding its structure-function relationships, enzymatic activity, and its biological implications. By producing recombinant B3GNT7, researchers aim to elucidate its role in glycan biosynthesis and its impact on cellular interactions. This is particularly significant in developing therapeutic strategies that can manipulate glycosylation patterns for disease intervention. Understanding B3GNT7's functional mechanisms could pave the way for new diagnostic markers and targeted therapies, enhancing our ability to address diseases associated with glycan abnormalities. The ongoing research further investigates potential applications in biotechnology and medicine, exploring how recombinant B3GNT7 can be utilized in drug development and the engineering of glycan-based therapeutics.
